sustained-release pharmaceutical tablet and process for preparation thereof

w New Patents

4415573

N O V E L U R A C I L D E R I V A T I V E S , P R O C E S S F O R P R E P A R I N G T H E

S A M E A N D A P H A R M A C E U T I C A L C O M P O S I T I O N C O N T A I N I N G

T H E S A M E

Klyoshlge Ochl, Katsuhlt Mlyamoto, Hlrokl MltsuL Yum~ko Tsuruma, Isao Matsunaga, Takashl Matsuno, Shlgeru Takanashl, Mlnoru Shmdo, Kawagoe, Japan assigned to Chugal Selyaku Kabushlkl Kalsha

- - (CHm.CH)n--~- R5

R6

4415547

S U S T A I N E D - R E L E A S E P H A R M A C E U T I C A L T A B L E T

A N D P R O C E S S F O R P R E P A R A T I O N T H E R E O F

Andrew B Yu, Phflhp John assigned to Sterhng Drug Inc

A sustained-release pharmaceutical tablet con- SlStxng essentially of drug pellets encapsulated with a water-soluble film-forming substance and a water-insoluble film-forming substance and blended and compressed into tablet form with a compressible tableting mixture and a process for preparation thereof are disclosed

Novel uracil derivatives of the formula See Pa- tentJor Chemical Structure (wherein R1, R2 R3 and X are defined in the description) and their pharmaceutically acceptable salts, process for preparing the same and pharmaceutical com- position containing the same are disclosed The uracil derivatives have good antltumor activity and, therefore, are useful as antltumor prepara- tion

4414224

P H A R M A C E U T I C A L C O M P O S I T I O N A N D M E T H O D S

F O R P R O D U C I N G D O P A M I N E A G O N I S T A C T I V I T Y

Wllham Huffman, James W Wilson assigned to SmtthKlme Beckman Corporation

4415564

P H A R M A C E U T I C A L P R E P A R A T I O N F O R T R E A T I N G

G L A U C O M A A N D O C U L A R H Y P E R T E N S I O N

Glancesare Gamba, Luclano Bonomi, Nyon, Switzerland assigned to Dlspersa AG

Pharmaceutical preparations for treating glaucoma and ocular hypertension, containing guanethidlne or a pharmaceutically acceptable salt thereof and a specific beta2-receptor agonlst m relative quantities of 20 ! to 1 5 in an aqueous solution

R I (CH2).

o :

OH

Methods and compositions using as active in- gredients 2-(3H)-lndolones whose structures having an amlnoalkyl substltuent at position 4 and a hydroxy group at position 7 of the ln- dolone nucleus are used to produce selective dopamlnerglc activity resulting in Improved kid- ney function, relief of the symptoms of conges- tive heart failure, long lasting anti-hypertensive activity and anti-anginal activity A species of the active Ingredients is 4-dl-n- propylamlnoethyl-7-hydroxy-2(3 H)-lndolone or its salts